<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670407</url>
  </required_header>
  <id_info>
    <org_study_id>201810001</org_study_id>
    <nct_id>NCT03670407</nct_id>
  </id_info>
  <brief_title>Follicular Activation by Fragmentation of Ovarian Tissue</brief_title>
  <acronym>FAFOT</acronym>
  <official_title>Follicular Activation by Fragmentation of Ovarian Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Podobnik Maternity and Gynecology Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Podobnik Maternity and Gynecology Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the chances of increasing the number of
      antral follicles in ovarian tissue of patients with diminished ovarian reserve by activation
      of primordial follicles through ovarian cortex fragmentation. Secondary objectives are to
      assess potential association with the number of oocytes retrieved and pregnancy rates after
      IVF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antral follicle count</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of oocytes retrieved</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diminished Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who opt not to go ahead with ovarian fragmentation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who opt for ovarian fragmentation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ovarian tissue fragmentation</intervention_name>
    <description>Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. previous ≥ 2 poor ovarian responds (≤ 3 retrieved oocytes) in an antagonist cycle with
             a minimum of 225 IU gonadotropins a day or corifollitropin 150 mcg) in patients &gt;35 i
             &lt;40 years

          2. previous cycle with ≤ 3 retrieved oocytes) in an antagonist cycle with a minimum of
             225 IU gonadotropins a day or corifollitropin 150 mcg) in patients &gt;35 i &lt;40 years
             with antral follicle count (AFC) ≤ 5 i/ili antiM¸ulelrian hormone (AMH) ≤ 6.5pmol/L

          3. premature ovarian insufficiency according to European Society of Human Reproduction
             and Embryology (ESHRE) development group, 2015 in patients 18-40 years

          4. undetectable AMH serum levels and follitropin (FSH) &gt;35 IU/ml in two serum samples
             separated by at least 4 weeks

        Exclusion Criteria:

          1. clinical/ultrasonographical signs of endometriosis

          2. previous ovarian/pelvic surgery

          3. previous gonadotoxic treatment

          4. genito-urinary tract malformations

          5. extreme male infertility ( &lt;10 000 progressively motile sperms in the semen sample)

          6. inform consent unsigned -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miro S Alebić</last_name>
    <role>Principal Investigator</role>
    <affiliation>Podobnik Maternity and Gynecology Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miro S Alebić, MD, PhD</last_name>
    <phone>+38516398001</phone>
    <email>msalebic@podobnik.hr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Milan D Milenkovic, MD, PhD</last_name>
    <email>milan.d.milenkovic@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Podobnik Maternity and Gynecology Hospital</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miro S Alebić, MD,PhD</last_name>
      <phone>+38516398001</phone>
      <email>msalebic@podobnik.hr</email>
    </contact>
    <contact_backup>
      <last_name>Slava Podobnik Šarkanji, prof, MD, PhD</last_name>
      <phone>+38516398000</phone>
      <email>slava.podobnik@podobnik.hr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>September 13, 2018</last_update_submitted>
  <last_update_submitted_qc>September 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Podobnik Maternity and Gynecology Hospital</investigator_affiliation>
    <investigator_full_name>Miro Šimun Alebić</investigator_full_name>
    <investigator_title>Head of human reproduction unit</investigator_title>
  </responsible_party>
  <keyword>Premature Ovarian Failure</keyword>
  <keyword>Infertility, Female</keyword>
  <keyword>Ovarian tissue fragmentation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

